72 related articles for article (PubMed ID: 22154379)
1. Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals.
Bozhinov A; Handzhiyski Y; Genov K; Daskalovska V; Niwa T; Ivanov I; Mironova R
J Allergy Clin Immunol; 2012 Mar; 129(3):855-858.e6. PubMed ID: 22154379
[No Abstract] [Full Text] [Related]
2. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
Abdul-Ahad AK; Galazka AR; Revel M; Biffoni M; Borden EC
Cytokines Cell Mol Ther; 1997 Mar; 3(1):27-32. PubMed ID: 9287241
[TBL] [Abstract][Full Text] [Related]
3. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.
van Beers MM; Sauerborn M; Gilli F; Hermeling S; Brinks V; Schellekens H; Jiskoot W
J Immunol Methods; 2010 Jan; 352(1-2):32-7. PubMed ID: 19857496
[TBL] [Abstract][Full Text] [Related]
4. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
Gneiss C; Koudouovoh-Tripp PM; Ropele S; Gotwald T; Ehling R; Lutterotti A; Aichner F; Ladurner G; Eggers C; Schautzer F; Künz B; Millonig A; Aspeck E; Reindl M; Berger T; Fazekas F; Deisenhammer F
Mult Scler; 2009 Dec; 15(12):1481-8. PubMed ID: 19965519
[TBL] [Abstract][Full Text] [Related]
5. Epitope specificity of neutralizing antibodies against IFN-beta.
Gneiss C; Reindl M; Berger T; Lutterotti A; Ehling R; Egg R; Deisenhammer F
J Interferon Cytokine Res; 2004 May; 24(5):283-90. PubMed ID: 15153311
[TBL] [Abstract][Full Text] [Related]
6. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
8. Recombinant antibody color resulting from advanced glycation end product modifications.
Butko M; Pallat H; Cordoba A; Yu XC
Anal Chem; 2014 Oct; 86(19):9816-23. PubMed ID: 25181536
[TBL] [Abstract][Full Text] [Related]
9. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
[No Abstract] [Full Text] [Related]
10. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
[TBL] [Abstract][Full Text] [Related]
11. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
[TBL] [Abstract][Full Text] [Related]
12. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
Bojar M; Zajac M; Meluzínová E; Houžvičková E; Libertinová J; Lišková P; Mat'oška V; Nyč O; Mináriková M
Mult Scler; 2010 Dec; 16(12):1529-30; author reply 1531-2. PubMed ID: 20829243
[No Abstract] [Full Text] [Related]
13. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
Giovannoni G; Barbarash O; Casset-Semanaz F; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Mult Scler; 2009 Feb; 15(2):219-28. PubMed ID: 18755819
[TBL] [Abstract][Full Text] [Related]
15. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
17. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
Farrell RA; Giovannoni G
Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
[TBL] [Abstract][Full Text] [Related]
18. Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox.
Sørensen PS
Mult Scler; 2012 Feb; 18(2):131-2. PubMed ID: 22312007
[No Abstract] [Full Text] [Related]
19. Glutaraldehyde is an effective cross-linker for production of antibodies against advanced glycation end-products.
Mera K; Nagai M; Brock JW; Fujiwara Y; Murata T; Maruyama T; Baynes JW; Otagiri M; Nagai R
J Immunol Methods; 2008 May; 334(1-2):82-90. PubMed ID: 18353354
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
Farrell R; Kapoor R; Leary S; Rudge P; Thompson A; Miller D; Giovannoni G
Mult Scler; 2008 Mar; 14(2):212-8. PubMed ID: 17986510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]